Frank:
Choose to bleieve what you like. I posted the link because I thought that the discussion was relevant. I learned a lot about the concept behind SIBI's approach from the discussion in the manuscript, and I thought that the background info might be of interest to others.
I got a chance to collaborate with Stephen Heinemann (on SIBI's SAB, Director of the Molecular Neurobiology Lab at the Salk Insitute, and a member of the National Academy) and John Morrison (a SIBI collaborator, Professor and Co-Director, Arthur Fishberg Research Center for Neurobiology, Mt Sinai) while I was V.P., Product Development at a San Diego-based reagents company. We were collaborating on the development of NMDAR-specific monoclonals, and the contact led to my initial interest in SIBI. Ron Evans (on SIBI's SAB, Professor and Director of the Gene Expression Laboratory at the Salk Insitute and a member of the National Academy) was my roommate while we were grad students together at UCLA. Mike Harpold, V.P. Research at SIBI, turns out to be an old friend from my second postdoc at USC School of Medicine (where I was a neurology fellow and, among other projects, made monoclonals against a demyelinating strain of neurotropic mouse hepatitis virus, Virology 131: 296-307). I trust the brains behind SIBI because I have first-hand experience with some of them.
I also trust that Watson and Crick, Board and SAB members at SIBI, will know if actin is a target of interest.
I find good scientists, and try to track them back to a business plan that has "explosion" potential. I then try to put together a basket of such high-risk companies. That's the way I invest in biotech, and it works. I have attempted to post stuff that I thought might both educate and bring out discussion. If my background leads me to post something that doesn't fit, either in reality or in your view, so be it.
I'm here to learn. I feel that both Alzheimer's programs at SIBI hold promise, as I did before you first posted to the thread.
Good luck in all your investments.
Rick |
